

TCI 600

REMSSEN

Organization _____

U. S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE

WASHINGTON, DC 20231

IF UNDELIVERABLE RETURN IN TEN DAYS

OFFICIAL BUSINESS

AN EQUAL OPPORTUNITY EMPLOYER

NIXIE

1402 1 04 04/23/04

RETURN TO SENDER
ATTEMPTED-NOT KNOWN
UNABLE TO FORWARD
RETURN TO SENDER

RECEIVED
APR 30 2004
TECH CENTER 1600/2900





UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/736,019	10/22/1996	ANDREW GOODEARL	04585/00200Q	3384
7590	04/20/2004		EXAMINER	
KRISTINA BIEKER-BRADY, PH.D. CLARK & ELBING LLP 176 FEDERAL STREET BOSTON, MA 021102214			GUCKER, STEPHEN	
			ART UNIT	PAPER NUMBER
			1647	

DATE MAILED: 04/20/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	08/736,019	GOODEARL ET AL.
	Examiner Stephen Gucker	Art Unit 1647
<i>-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --</i>		
Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.		
- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.		
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.		
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.		
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).		
Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).		
Status		
1) <input checked="" type="checkbox"/> Responsive to communication(s) filed on <u>23 May 2003</u> .		
2a) <input type="checkbox"/> This action is FINAL . 2b) <input checked="" type="checkbox"/> This action is non-final.		
3) <input type="checkbox"/> Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims		
4) <input checked="" type="checkbox"/> Claim(s) <u>132,136,137 and 139-143</u> is/are pending in the application.		
4a) Of the above claim(s) _____ is/are withdrawn from consideration.		
5) <input type="checkbox"/> Claim(s) _____ is/are allowed.		
6) <input checked="" type="checkbox"/> Claim(s) <u>132,136,137 and 139-142</u> is/are rejected.		
7) <input checked="" type="checkbox"/> Claim(s) <u>143</u> is/are objected to.		
8) <input type="checkbox"/> Claim(s) _____ are subject to restriction and/or election requirement.		
Application Papers		
9) <input type="checkbox"/> The specification is objected to by the Examiner.		
10) <input type="checkbox"/> The drawing(s) filed on _____ is/are: a) <input type="checkbox"/> accepted or b) <input type="checkbox"/> objected to by the Examiner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).		
11) <input type="checkbox"/> The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.		
Priority under 35 U.S.C. § 119		
12) <input type="checkbox"/> Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) <input type="checkbox"/> All b) <input type="checkbox"/> Some * c) <input type="checkbox"/> None of:		
1. <input type="checkbox"/> Certified copies of the priority documents have been received.		
2. <input type="checkbox"/> Certified copies of the priority documents have been received in Application No. _____.		
3. <input type="checkbox"/> Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).		
* See the attached detailed Office action for a list of the certified copies not received.		
Attachment(s)		
1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)		
2) <input checked="" type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)		
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____.		
4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.		
5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)		
6) <input type="checkbox"/> Other: _____.		

Response to Amendment

1. The request filed on 5/23/03 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 08/736,019 is acceptable and a CPA has been established. An action on the CPA follows.
2. It is noted by the Examiner that the request for the CPA did not include a request for entry of the after-final amendment filed 7/29/02, so the Examiner has acted upon the claims as pending before 7/29/02. To help clarify the situation, the Examiner has included a copy of the pending claims as acted upon in this Office Action at the end of this action. Immediately following this copy of the pending claims is a version of the claims with markings to show changes made that the Examiner believed was Applicant's intention, had Applicant included a request to enter the after-final amendment filed 7/29/02 along with the request for the CPA.
3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
4. Any objections or rejections made in a previous Office Action that are not herein reinstated have been withdrawn.
5. The Examiner would like to thank Applicant for the response to the previous request for information under 37 CFR 1.105. However, due to differing sequence listings in these patents and patent applications, the Examiner is forced to request further information.

6. Applicant and the assignee of this application are required under 37 CFR 1.105 to provide the following information that the examiner has determined is reasonably necessary to the examination of this application:

7. Because of the large number of sequences and fragments of sequences presented for examination in the instant claims and in multiple co-pending and allowed applications, the Examiner is making a request for a listing and identification of all applications that Applicants have filed that claim the instant sequences either as discrete SEQ ID NOs or fragments of larger sequences in any methods of administration and/or treatment. The Examiner is making this request because the sequence listings in some of these applications exceeds 300 SEQ ID NOs, and the numbering scheme between applications has not always remained constant, such that a SEQ ID NO in one application may not correspond to the same SEQ ID NO in another application. **In addition, the Examiner requests Applicants' assistance to provide a current update and identify which SEQ ID NOs correspond to which SEQ ID NOs currently being claimed in methods of use in the instant Application where the SEQ ID NOs are not identical. If fragments of larger sequences are being used or encoding nucleotide sequences, Applicants are requested to identify these sequences or subsequences by amino acid residue or nucleotide numbering. It is the Examiner's wish that with this update and identification, allowable subject matter in the instant Application can be more easily identified in relation to double-patenting issues, and these double-patenting issues resolved, so that the instant Application can proceed to allowance.**

Art Unit: 1647

8. Claims 132, 136-137, and 139-142 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 11 of U.S. Patent No. 6,204,241. Although the conflicting claims are not identical, they are not patentably distinct from each other because the polypeptides administered by the process steps recited in the instant application of a *method for inducing myelination of a neural cell by a glial cell* by using an amino acid sequence encoded by SEQ ID NO:154, or amino acid sequences comprising SEQ ID NO:188-189, or an amino acid sequence provided in SEQ ID NO:151, or amino acids 362-411 of SEQ ID NO:170, are polypeptides which are all contained within SEQ ID NO:170 of claim 11 of the instant patent which recites a *method for inducing myelination of a neural cell by a glial cell* comprising administering amino acids 51-422 of SEQ ID NO:170.

Furthermore, although the conflicting claims are not identical, they are not patentably distinct from each other because the patented claim recites the administration of a polypeptide (amino acids 51-422 of SEQ ID NO:170) and the instant claims recite the use of fragments of said polypeptide (SEQ ID NO:188 is residues 350-411 of SEQ ID NO:170, SEQ ID NO:189 is residues 350-422 of SEQ ID NO:170, SEQ ID NO:154 encodes a sequence found within SEQ ID NO:170, SEQ ID NO:151 is found within SEQ ID NO:170, and SEQ ID NO:170 is identical between the patent and the instant Application). The patented claim is a sub-genus of the instant claims because it recites a genus that is smaller than the instant genus, but completely encompassed by the claimed instant genus. Therefore, a species-genus relationship exists between the patented claim and the instant claims, and the patented claim renders the instant claims

Art Unit: 1647

obvious because the patented claim anticipates the instant claims and the patented species or sub-genus renders the instant genus claims obvious. See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985).

The grounds for this rejection could be obviated by having the after-final amendment filed 7/29/02 entered into the instant Application (most easily accomplished by re-submitting the amendment).

9. Claims 132, 136-137, and 139-142 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-2 of U.S. Patent No. 6,635,249 B1. Although the conflicting claims are not identical, they are not patentably distinct from each other because the patented claim recites the administration of a polypeptide (recombinant human GGF2) and the instant claims recite the use of fragments of said polypeptide (SEQ ID NO:188 is residues 350-411 of full-length recombinant human GGF2, SEQ ID NO:189 is residues 350-422 of full-length recombinant human GGF2, SEQ ID NO:154 encodes a sequence found within full-length recombinant human GGF2, and SEQ ID NO:151 is found within full-length recombinant human GGF2). The patented claim is a sub-genus of the instant claims because it recites a genus that is smaller than the instant genus, but completely encompassed by the claimed instant genus. Therefore, a species-genus relationship exists between the patented claim and the instant claims, and the patented claim renders the instant claims obvious because the patented claim anticipates the instant

claims and the patented species or sub-genus renders the instant genus claims obvious. See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985).

The grounds for this rejection could be obviated by having the after-final amendment filed 7/29/02 entered into the instant Application (most easily accomplished by re-submitting the amendment).

10. Claims 132, 136-137, and 139-142 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of co-pending U.S. Application No. 08/461,097. Although the conflicting claims are not identical, they are not patentably distinct from each other because the co-pending claim recites the administration of a polypeptide (SEQ ID NO:324) and the instant claims recite the use of fragments of said polypeptide (SEQ ID NO:188 is residues 350-411 of SEQ ID NO:324, SEQ ID NO:189 is residues 350-422 of SEQ ID NO:324, SEQ ID NO:154 encodes a sequence found within SEQ ID NO:324, and SEQ ID NO:151 is found within SEQ ID NO:324). The co-pending claim is a sub-genus of the instant claims because it recites a genus that is smaller than the instant genus, but completely encompassed by the claimed instant genus. Therefore, a species-genus relationship exists between the patented claim and the instant claims, and the patented claim renders the instant claims obvious because the patented claim anticipates the instant claims and the patented species or sub-genus renders the instant genus claims obvious. See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re*

Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985).

The grounds for this rejection could be obviated by having the after-final amendment filed 7/29/02 entered into the instant Application (most easily accomplished by re-submitting the amendment).

11. Claims 132, 136-137, and 139-142 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 145 of co-pending U.S. Application No. 08/471,833. Although the conflicting claims are not identical, they are not patentably distinct from each other because the polypeptides administered by the process steps recited in the instant Application of *a method for inducing myelination of a neural cell by a glial cell* by using an amino acid sequence encoded by SEQ ID NOS:154-159, or an amino acid sequence provided in SEQ ID NOS:151-152, or an amino acid sequence encoded by nucleotides 161-310 of SEQ ID NO:150, are polypeptides which are identical to the polypeptides administered in the co-pending Application which recites *a method for inducing myelination of a neural cell by a glial cell*. The co-pending claim is a sub-genus of the instant claims because it recites a genus that is smaller (a method for treating multiple sclerosis) than the instant genus (a method for inducing myelination of a neural cell by a glial cell), but completely encompassed by the claimed instant genus. Therefore, a species-genus relationship exists between the co-pending claim and the instant claims, and the co-pending claim renders the instant claims obvious because the co-pending claim anticipates the instant claims and the co-pending species or sub-genus renders the instant genus claims

obvious. See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985).

The grounds for this rejection could NOT be obviated by having the after-final amendment filed 7/29/02 entered into the instant Application.

12. Claims 132 and 139-140 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 11 of co-pending U.S. Application No. 09/530,884. Although the conflicting claims are not identical, they are not patentably distinct from each other because the polypeptides administered by the process steps recited in the instant Application of a *method for inducing myelination of a neural cell by a glial cell* by using an amino acid sequence encoded by SEQ ID NO:158 or an amino acid sequence encoded by nucleotides 161-310 of SEQ ID NO:150, are polypeptides which are fragments of the polypeptides administered in the co-pending Application which recites a method of treating a mammal suffering from or *susceptible to stroke, brain or spinal cord injury or ischemia, or heart attack, comprising administering to the mammal a therapeutically effective amount of a neuregulin, wherein the neuregulin is encoded by a nucleic acid that comprises one of SEQ ID NOS:49, 51, and 53.* SEQ ID NO:49 of the co-pending Application encodes within itself the amino acid sequence encoded by nucleotides 161-310 of SEQ ID NO:150 of the instant Application. SEQ ID NO:51 of the co-pending Application encodes within itself the amino acid sequence encoded by SEQ ID NO:158 of the instant Application. The co-pending claim is a sub-genus of the instant claims because it recites a genus that is

smaller (because the sequences used in the methods are larger sequences) than the instant genus (because the sequences used in the instant methods are encoded fragments of the larger sequences in the co-pending Application), but completely encompassed by the claimed instant genus. Therefore, a species-genus relationship exists between the co-pending claim and the instant claims, and the co-pending claim renders the instant claims obvious because the co-pending claim anticipates the instant claims and the co-pending species or sub-genus renders the instant genus claims obvious. See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985).

The grounds for this rejection could NOT be obviated by having the after-final amendment filed 7/29/02 entered into the instant Application.

13. Claim 143 is objected to as being dependent upon a rejected claim.
14. No claim is allowed.
15. As allowable subject matter has been indicated, applicant's reply must either comply with all formal requirements or specifically traverse each requirement not complied with. See 37 CFR 1.111(b) and MPEP § 707.07(a).
16. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technical Center 1600 general number which is (571) 272-1600.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephen Gucker whose telephone number is (571) 272-

0883. The examiner can normally be reached on Monday to Friday from 0930 to 1800.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached at (571) 272-0887. The fax phone number for this Group is currently (703) 872-9306.

SG

Stephen Gucker

April 14, 2004

Gary L. Kunz
GARY KUNZ
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

132. (Amended) A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain, wherein said epidermal growth factor-like domain comprises an [the] amino acid sequence [of] which is identical to an amino acid sequence encoded by a GGF/p185 erb B2 ligand gene, and wherein said amino acid sequence comprises an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of:

SEQ ID NO: 154 (EGFL1);

SEQ ID NO: 155 (EGFL2);

SEQ ID NO: 156 (EGFL3);

SEQ ID NO: 157 (EGFL4);

SEQ ID NO: 158 (EGFL5);

SEQ ID NO: 159 (EGFL6); and

amino acids 54-103 encoded by SEQ ID NO: 150

[sufficient to induce myelination of a neural cell by said glial cell].

Sub D2

136. (Amended) [The method of claim 133] A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain,

136. (Twice amended) A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain, wherein said epidermal growth [factor like] factor-like domain comprises the [polypeptide encoded by] amino acid sequence set forth in SEQ ID NO: 188[, wherein the human C/D'-segment polypeptide encoded by SEQ ID NO: 179 is immediately C-terminal to the human C-segment polypeptide encoded by SEQ ID NO: 177].

137. (Twice amended) A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain, wherein said epidermal growth [factor like] factor-like domain comprises the [polypeptide encoded by] amino acid sequence set forth in SEQ ID NO: 189[, wherein the bovine C/D'-segment polypeptide encoded by SEQ ID NO: 143 is immediately C-terminal to the human C-segment polypeptide encoded by SEQ ID NO: 177, and the human D-segment polypeptide encoded by SEQ ID NO: 180 is immediately C-terminal to the polypeptide encoded by SEQ ID NO: 143].

In the Drawings:

Replace Figs. 31I-31L with the corrected copies of Figs. 31I-31L, provided herewith.

Sub D 29
Cont

137

wherein said epidermal growth factor like domain [further] comprises the polypeptide encoded by SEQ ID NO: 188, wherein the human C/D'-segment polypeptide encoded by SEQ ID NO: 179 [178] [, wherein SEQ ID NO: 178] is immediately C-terminal to the human C-segment polypeptide encoded by SEQ ID NO: 177.

137. (Amended) [The method of claim 133] A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain, wherein said epidermal growth factor like domain [further] comprises the polypeptide encoded by SEQ ID NO: 189 [SEQ ID NO: 179], wherein the bovine C/D' -segment polypeptide encoded by SEQ ID NO: 143 [42] is immediately C-terminal to the human C-segment polypeptide encoded by SEQ ID NO: 177, and the human D-segment polypeptide encoded by SEQ ID NO: 180 is immediately C-terminal to the polypeptide encoded by SEQ ID NO: 143]

139. (Amended) The method of claim 132, 136, 137 or 141, wherein said [A] method [for inducing myelination of a neural cell by a glial cell,] further [comprising] comprises contacting said cell with [an amount of] a polypeptide which binds the p185 erb B2 receptor[, sufficient to induce myelination of a neural cell by said glial cell].

C 1
140. (Amended) The method of claim 132, 136, 137 or 141, wherein said polypeptide is [A method of inducing myelination of a neural cell by a glial cell, comprising contacting said glial cell with an amount of] a recombinant polypeptide with glial cell mitogenic activity [sufficient to induce myelination of a neural cell by said glial cell].

Add new claims 141-143.

C 8
--141. A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain, wherein said epidermal growth factor-like domain comprises an amino acid sequence which is identical to an amino acid sequence encoded by a GGF/p185 erb B2 ligand gene, and wherein said amino acid sequence is selected from the group consisting of:

SEQ ID NO: 151;

SEQ ID NO: 152; and

amino acids 362-411 of SEQ ID NO: 170,

wherein said contacting with said polypeptide is sufficient to induce myelination of said neural cell by said glial cell.



PATENT
ATTORNEY DOCKET NO. 04585/00200Q

16K1
#22E/HW
02/12/02

FEB 05 2002

RECEIVED
TECH CENTER 1600/2900

Certificate of Mailing: Date of Deposit: January 17, 2002

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Roselynn D. Scarfo

Printed name of person mailing correspondence

Roselynn D. Scarfo

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Goodearl et al.

Art Unit: 1647

Serial No.: 08/736,019

Examiner: Gucker, S.

Filed: October 22, 1996

Customer No.: 21559

Title: GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE

Assistant Commissioner for Patents
Washington, D.C. 20231

REPLY TO EXAMINER'S ACTION

In reply to the Examiner's Action mailed in the above-captioned case on October 29, 2001, Applicants submit the following amendments and remarks.

AMENDMENTS

In the claims

Please amend claims 142 and 143 to read as follows:

142. (Amended) The method of claim 141, wherein said amino acid sequence is SEQ ID NO: 151.

E/

143. (Amended) The method of claim 141, wherein said amino acid sequence is SEQ ID NO: 152.

Version with markings to show changes made

In the claims:

A marked-up version of claims 132, 139, 140, and 141 is presented below.

132. (Twice Amended) A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain, wherein said epidermal growth factor-like domain comprises an amino acid sequence which is identical to an amino acid sequence encoded by a GGF/p185 erb B2 ligand gene, and wherein said amino acid sequence comprises an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of:

[SEQ ID NO: 154 (EGFL1);]

SEQ ID NO: 155 (EGFL2);

SEQ ID NO: 156 (EGFL3);

SEQ ID NO: 157 (EGFL4);

SEQ ID NO: 158 (EGFL5);

SEQ ID NO: 159 (EGFL6); and

amino acids 54-103 encoded by SEQ ID NO: 150.

139. (Twice Amended) The method of claim 132 [, 136, 137] or 141, wherein said method further comprises contacting said cell with a polypeptide which binds the p185 erb B2 receptor.

140. (Twice Amended) The method of claim 132 [, 136, 137] or 141, wherein said polypeptide is a recombinant polypeptide with glial cell mitogenic activity.

141. (Twice Amended) A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain, wherein said epidermal growth factor-like domain comprises an amino acid sequence which is identical to an amino acid sequence encoded by a GGF/p185 erb B2 ligand gene, and wherein said amino acid sequence comprises the amino acid sequence provided in [is selected from the group consisting of:

SEQ ID NO: 151;]

SEQ ID NO: 152 [; and

amino acids 362-411 of SEQ ID NO: 170],

wherein said contacting with said polypeptide is sufficient to induce myelination of said neural cell by said glial cell.

NOTICE OF DRAFTSPERSON'S PATENT DRAWING REVIEW

The drawing(s) filed (insert date) 5-30-00 are:

A. approved by the Draftsperson under 37 CFR 1.84 or 1.152.
 B. objected to by the Draftsperson under 37 CFR 1.84 or 1.152 for the reasons indicated below. The Examiner will require submission of new, corrected drawings when necessary. Corrected drawing must be submitted according to the instructions on the back of this notice.

<p>1. DRAWINGS. 37 CFR 1.84(a): Acceptable categories of drawings: Black ink. Color. — Color drawings are not acceptable until petition is granted. Fig(s) _____</p> <p>Pencil and non black ink not permitted. Fig(s) _____</p> <p>2. PHOTOGRAPHS. 37 CFR 1.84 (b) 1 full-tone set is required. Fig(s) _____ — Photographs not properly mounted (must use Bristol board or photographic double-weight paper). Fig(s) _____ — Poor quality (half-tone). Fig(s) <u>503, 513, 52</u></p> <p>3. TYPE OF PAPER. 37 CFR 1.84(c) — Paper not flexible, strong, white, and durable. Fig(s) _____ — Erasures, alterations, overwritings, interlineations, folds, copy machine marks not accepted. Fig(s) _____ — Mylar, velum paper is not acceptable (too thin). Fig(s) _____</p> <p>4. SIZE OF PAPER. 37 CFR 1.84(f): Acceptable sizes: — 21.0 cm by 29.7 cm (DIN size A4) — 21.6 cm by 27.9 cm (8 1/2 x 11 inches) — All drawing sheets not the same size. Sheet(s) <u>514, 516, 517, 518, 519</u> — Drawings sheet not an acceptable size. Fig(s) _____</p> <p>5. MARGINS. 37 CFR 1.84(g): Acceptable margins: Top 2.5 cm Left 2.5cm Right 1.5 cm Bottom 1.0 cm SIZE: A4 Size Top 2.5 cm Left 2.5 cm Right 1.5 cm Bottom 1.0 cm SIZE: 8 1/2 x 11 Margins not acceptable. Fig(s) <u>310, 319, 371, 372, 53</u> — Top (T) _____ Left (L) _____ — Right (R) _____ Bottom (B) _____</p> <p>6. VIEWS. 37 CFR 1.84(h) REMINDER: Specification may require revision to correspond to drawing changes. Partial views. 37 CFR 1.84(h)(2) — Brackets needed to show figure as one entity. Fig(s) _____ — Views not labeled separately or properly. Fig(s) _____ — Enlarged view not labeled separately or properly. Fig(s) _____</p> <p>7. SECTIONAL VIEWS. 37 CFR 1.84 (h)(3) — Hatching not indicated for sectional portions of an object. Fig(s) _____ — Sectional designation should be noted with Arabic or Roman numbers. Fig(s) _____</p>	<p>8. ARRANGEMENT OF VIEWS. 37 CFR 1.84(i) — Words do not appear on a horizontal, left-to-right fashion when page is either upright or turned so that the top becomes the right side, except for graphs. Fig(s) _____</p> <p>9. SCALE. 37 CFR 1.84(k) — Scale not large enough to show mechanism without crowding when drawing is reduced in size to two-thirds in reproduction. Fig(s) _____</p> <p>10. CHARACTER OF LINES, NUMBERS, & LETTERS. 37 CFR 1.84(l) — Lines, numbers & letters not uniformly thick and well defined, clean, durable, and black (poor line quality). Fig(s) _____</p> <p>11. SHADING. 37 CFR 1.84(m) — Solid black areas pale. Fig(s) _____ — Solid black shading not permitted. Fig(s) _____ — Shade lines, pale, rough and blurred. Fig(s) _____</p> <p>12. NUMBERS, LETTERS, & REFERENCE CHARACTERS. 37 CFR 1.84(p) — Numbers and reference characters not plain and legible. Fig(s) _____ — Figure legends are poor. Fig(s) <u>514, 515</u> — Numbers and reference characters not oriented in the same direction as the view. 37 CFR 1.84(p)(1) Fig(s) _____ — English alphabet not used. 37 CFR 1.84(p)(2) Fig(s) _____ — Numbers, letters and reference characters must be at least .32 cm (1/8 inch) in height. 37 CFR 1.84(p)(3) Fig(s) _____</p> <p>13. LEAD LINES. 37 CFR 1.84(q) — Lead lines cross each other. Fig(s) _____ — Lead lines missing. Fig(s) _____</p> <p>14. NUMBERING OF SHEETS OF DRAWINGS. 37 CFR 1.84(i) — Sheets not numbered consecutively, and in Arabic numerals beginning with number 1. Sheet(s) _____</p> <p>15. NUMBERING OF VIEWS. 37 CFR 1.84(u) — Views not numbered consecutively, and in Arabic numerals, beginning with number 1. Fig(s) _____</p> <p>16. CORRECTIONS. 37 CFR 1.84(w) — Corrections not made from prior PTO-948 dated _____</p> <p>17. DESIGN DRAWINGS. 37 CFR 1.152 — Surface shading shown not appropriate. Fig(s) _____ — Solid black shading not used for color contrast. Fig(s) _____</p>
COMMENTS	

REVIEWER DATE 5-31-00 TELEPHONE NO. 203-355-8730

ATTACHMENT TO PAPER NO.

INFORMATION ON HOW TO EFFECT DRAWING CHANGES

1. Correction of Informalities-37 CFR 1.85

File new drawings with the changes incorporated therein. The application number or the title of the invention, inventor's name, docket number (if any), and the name and telephone number of a person to call if the Office is unable to match the drawings to the proper application, should be placed on the back of each sheet of drawings in accordance with 37 CFR 1.84(c). Applicant may delay filing of the new drawings until receipt of the Notice of Allowability (PTOL-37). Extensions of time may be obtained under the provisions of 37 CFR 1.136. The drawing should be filed as a separate paper with a transmittal letter addressed to the Drawing Processing Branch.

2. Timing for Corrections

Applicant is required to submit acceptable corrected drawings within the three-month shortened statutory period set in the Notice of Allowability (PTOL-37). If a correction is determined to be unacceptable by the Office, applicant must arrange to have acceptable corrections resubmitted within the original three-month period to avoid the necessity of obtaining an extension of time and paying the extension fee. Therefore, applicant should file corrected drawings as soon as possible.

Failure to take corrective action within set (or extended) period will result in ABANDONMENT of the Application.

3. Corrections other than Informalities Noted by the Drawing Review Branch on the Form PTO-948

All changes to the drawings, other than informalities noted by the Drawing Review Branch, MUST be approved by the examiner before the application will be allowed. No changes will be permitted to be made, other than correction of informalities, unless the examiner has approved the proposed changes.

Notice of References Cited		Application/Control No. 08/736,019	Applicant(s)/Patent Under Reexamination GOODEARL ET AL.	
		Examiner Stephen Gucker	Art Unit 1647	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-6,635,249 B1	10-2003	Marchionni et al.	424/145.1
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.